Will Refurbished Xi Systems Expand ISRG's Presence from Hospitals to ASCs?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Should l Buy ISRG?
Source: NASDAQ.COM
Intuitive Surgical's Market Strategy: Intuitive Surgical is leveraging refurbished da Vinci Xi systems to penetrate cost-sensitive markets and ambulatory surgery centers, enhancing its market access without compromising the pricing of its flagship da Vinci 5 systems.
Robotics Adoption by Zimmer Biomet: Zimmer Biomet is focusing on its ROSA robotics strategy to boost growth, reporting significant adoption in knee implants and anticipating enhancements to deepen market penetration.
Stereotaxis' GenesisX Platform: Stereotaxis is advancing its GenesisX robotic surgery platform, which has received CE Mark approval in Europe and is set for U.S. launch in 2026, aiming to lower barriers to adoption in robotic electrophysiology procedures.
Stock Performance and Future Outlook: Intuitive Surgical's stock has outperformed the industry, with a projected earnings increase for 2025, while the AI sector is expected to see a new wave of growth, presenting investment opportunities in emerging companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 499.530
Low
575.00
Averages
637.32
High
740.00
Current: 499.530
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's GLP-1 Drug Competition Intensifies
- Intensified Market Competition: Novo Nordisk's oral version of the GLP-1 drug Ozempic has reignited competition with Eli Lilly in the weight loss drug market, highlighting the fierce rivalry and innovation potential within the pharmaceutical industry.
- Surgeon Robot Demand Growth: By the end of 2025, Intuitive Surgical had 11,106 da Vinci surgical robots in operation, a 12% increase, with surgeries performed rising 18%, indicating a sustained demand for robotic surgery in the healthcare sector.
- Relative Valuation Appeal: Although Intuitive Surgical's price-to-earnings ratio stands at 61, which is below the five-year average of 71, it presents a relatively attractive investment opportunity for growth-focused investors looking for value.
- AI Technology Application Prospects: Intuitive Surgical is incorporating artificial intelligence into its surgical robots, with the potential for these robots to perform surgeries in the future, enhancing its competitive edge and technological leadership in the market.
See More
Intuitive Surgical's Growth Potential in Medical Devices
- Intensifying Market Competition: Novo Nordisk and Eli Lilly are fiercely competing in the GLP-1 weight loss drug market, with Novo's pill version of Ozempic reigniting rivalry, potentially reshaping the overall market landscape.
- Surge in Robotic Surgery Demand: By the end of 2025, Intuitive Surgical had 11,106 da Vinci surgical robots in operation, a 12% increase from 9,902 at the end of 2024, indicating strong demand for robotic surgery in the medical field.
- Financial Metrics Insight: Intuitive Surgical's price-to-earnings ratio stands at 61, below the five-year average of 71, suggesting that while the stock appears expensive on an absolute basis, it remains relatively cheap compared to historical valuations, attracting growth investors.
- AI Integration Prospects: The company is incorporating artificial intelligence into surgical procedures, with the potential for the da Vinci system to perform surgeries in the future, and as surgical volumes increase, demand is expected to remain robust, further driving company growth.
See More
Intuitive Surgical: A Resilient Medtech Stock for Market Crashes
- Market Leadership: Intuitive Surgical, as the leader in the robotic surgery market, maintains a strong competitive advantage with its flagship Da Vinci surgical robot, ensuring hospitals prefer to stick with a familiar system to mitigate risks associated with new technologies.
- Continuous Innovation: The latest Da Vinci 5 robot features over 100 design innovations that enhance operating room workflows and data analysis capabilities, ensuring that its platforms consistently meet surgeons' technological needs, thereby increasing customer loyalty and market competitiveness.
- Diverse Revenue Streams: Intuitive Surgical generates revenue not only from selling or leasing robotic platforms but also from disposable instruments and accessories, as well as maintenance service contracts, ensuring a stable and sustainable income flow.
- Strong Financial Performance: Over the past three years, Intuitive Surgical's stock price has surged by 100%, with ongoing revenue and profit growth allowing it to maintain stable income even during economic downturns, showcasing its resilience and attractiveness in volatile markets.
See More
Intuitive Surgical's Dominance in Robotic Surgery Market
- Market Leadership: Intuitive Surgical dominates the robotic surgery market, with its flagship Da Vinci surgical robot being the training tool for most surgeons, leading hospitals to continue using this platform after investing millions, thereby solidifying the company's competitive advantage.
- Continuous Innovation: The latest Da Vinci 5 robot features over 100 design innovations aimed at improving operating room workflows and data analysis capabilities, ensuring surgeons receive the necessary technological support, which enhances surgical efficiency and patient safety.
- Revenue Growth Potential: Intuitive Surgical generates revenue through the sale and leasing of surgical platforms, as well as the replacement of disposable instruments and accessories, which yield greater quarterly revenue than full platform sales, showcasing its strong recurring revenue capabilities.
- Resilience to Economic Fluctuations: Patients require Da Vinci-guided surgeries, such as hernia repairs and gallbladder surgeries, regardless of the economic backdrop, indicating that Intuitive Surgical can maintain revenue growth even during downturns, further establishing its appeal as a long-term investment.
See More
Rising Healthcare Costs Highlight Intuitive Surgical's Strong Market Position
- Healthcare Spending Outlook: Fidelity reports that a 65-year-old retiring in 2025 could expect to spend an average of $172,500 on medical and healthcare expenses, highlighting the lucrative potential of the healthcare sector and attracting investor interest.
- Surgical System Performance: Intuitive Surgical's da Vinci systems have performed over 16 million procedures worldwide, utilized in 72 countries, with a procedure commencing every 11.75 seconds, demonstrating its significant impact in the minimally invasive surgery market.
- Sustained Growth Momentum: In its recent earnings report, Intuitive Surgical noted an 18% year-over-year increase in global procedures, with da Vinci system installations rising from 493 to 532, and revenue increasing by 19%, showcasing the company's ongoing expansion capabilities in the market.
- AI Technology Application: Intuitive Surgical leverages data from over 10 million procedures to enhance the Ion system's navigation capabilities using AI, addressing the CT-to-body divergence issue in lung biopsies, thereby further strengthening its product competitiveness and market adaptability.
See More
Analysis of QQQI ETF's 52-Week Price Range
- Price Range Analysis: QQQI ETF's 52-week low is $41.1701 per share and high is $55.93, with the last trade at $52.51, indicating stability and potential investment opportunities in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets.
See More
Novo Nordisk's GLP-1 Drug Competition Intensifies
- Intensified Market Competition: Novo Nordisk's oral version of the GLP-1 drug Ozempic has reignited competition with Eli Lilly in the weight loss drug market, highlighting the fierce rivalry and innovation potential within the pharmaceutical industry.
- Surgeon Robot Demand Growth: By the end of 2025, Intuitive Surgical had 11,106 da Vinci surgical robots in operation, a 12% increase, with surgeries performed rising 18%, indicating a sustained demand for robotic surgery in the healthcare sector.
- Relative Valuation Appeal: Although Intuitive Surgical's price-to-earnings ratio stands at 61, which is below the five-year average of 71, it presents a relatively attractive investment opportunity for growth-focused investors looking for value.
- AI Technology Application Prospects: Intuitive Surgical is incorporating artificial intelligence into its surgical robots, with the potential for these robots to perform surgeries in the future, enhancing its competitive edge and technological leadership in the market.
See More
Intuitive Surgical's Growth Potential in Medical Devices
- Intensifying Market Competition: Novo Nordisk and Eli Lilly are fiercely competing in the GLP-1 weight loss drug market, with Novo's pill version of Ozempic reigniting rivalry, potentially reshaping the overall market landscape.
- Surge in Robotic Surgery Demand: By the end of 2025, Intuitive Surgical had 11,106 da Vinci surgical robots in operation, a 12% increase from 9,902 at the end of 2024, indicating strong demand for robotic surgery in the medical field.
- Financial Metrics Insight: Intuitive Surgical's price-to-earnings ratio stands at 61, below the five-year average of 71, suggesting that while the stock appears expensive on an absolute basis, it remains relatively cheap compared to historical valuations, attracting growth investors.
- AI Integration Prospects: The company is incorporating artificial intelligence into surgical procedures, with the potential for the da Vinci system to perform surgeries in the future, and as surgical volumes increase, demand is expected to remain robust, further driving company growth.
See More
Intuitive Surgical: A Resilient Medtech Stock for Market Crashes
- Market Leadership: Intuitive Surgical, as the leader in the robotic surgery market, maintains a strong competitive advantage with its flagship Da Vinci surgical robot, ensuring hospitals prefer to stick with a familiar system to mitigate risks associated with new technologies.
- Continuous Innovation: The latest Da Vinci 5 robot features over 100 design innovations that enhance operating room workflows and data analysis capabilities, ensuring that its platforms consistently meet surgeons' technological needs, thereby increasing customer loyalty and market competitiveness.
- Diverse Revenue Streams: Intuitive Surgical generates revenue not only from selling or leasing robotic platforms but also from disposable instruments and accessories, as well as maintenance service contracts, ensuring a stable and sustainable income flow.
- Strong Financial Performance: Over the past three years, Intuitive Surgical's stock price has surged by 100%, with ongoing revenue and profit growth allowing it to maintain stable income even during economic downturns, showcasing its resilience and attractiveness in volatile markets.
See More
Intuitive Surgical's Dominance in Robotic Surgery Market
- Market Leadership: Intuitive Surgical dominates the robotic surgery market, with its flagship Da Vinci surgical robot being the training tool for most surgeons, leading hospitals to continue using this platform after investing millions, thereby solidifying the company's competitive advantage.
- Continuous Innovation: The latest Da Vinci 5 robot features over 100 design innovations aimed at improving operating room workflows and data analysis capabilities, ensuring surgeons receive the necessary technological support, which enhances surgical efficiency and patient safety.
- Revenue Growth Potential: Intuitive Surgical generates revenue through the sale and leasing of surgical platforms, as well as the replacement of disposable instruments and accessories, which yield greater quarterly revenue than full platform sales, showcasing its strong recurring revenue capabilities.
- Resilience to Economic Fluctuations: Patients require Da Vinci-guided surgeries, such as hernia repairs and gallbladder surgeries, regardless of the economic backdrop, indicating that Intuitive Surgical can maintain revenue growth even during downturns, further establishing its appeal as a long-term investment.
See More
Rising Healthcare Costs Highlight Intuitive Surgical's Strong Market Position
- Healthcare Spending Outlook: Fidelity reports that a 65-year-old retiring in 2025 could expect to spend an average of $172,500 on medical and healthcare expenses, highlighting the lucrative potential of the healthcare sector and attracting investor interest.
- Surgical System Performance: Intuitive Surgical's da Vinci systems have performed over 16 million procedures worldwide, utilized in 72 countries, with a procedure commencing every 11.75 seconds, demonstrating its significant impact in the minimally invasive surgery market.
- Sustained Growth Momentum: In its recent earnings report, Intuitive Surgical noted an 18% year-over-year increase in global procedures, with da Vinci system installations rising from 493 to 532, and revenue increasing by 19%, showcasing the company's ongoing expansion capabilities in the market.
- AI Technology Application: Intuitive Surgical leverages data from over 10 million procedures to enhance the Ion system's navigation capabilities using AI, addressing the CT-to-body divergence issue in lung biopsies, thereby further strengthening its product competitiveness and market adaptability.
See More
Analysis of QQQI ETF's 52-Week Price Range
- Price Range Analysis: QQQI ETF's 52-week low is $41.1701 per share and high is $55.93, with the last trade at $52.51, indicating stability and potential investment opportunities in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets.
See More
